Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting Non-phase study NCT05949645

Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema

Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema — Active Not Recruiting • Non-phase study • Respiratory / COPD / Asthma…

📅 31 Mar 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Non-phase study
NCT ID
NCT05949645
Start
2023-08-15
Completion
2024-10-08
ClinicaliQ Trial Snapshot
  • Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema — Active Not Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT05949645.
  • Review the linked registry entry for study design, population, endpoints, and operational status.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this clinical trial is to test the feasibility of an implant for severe emphysema in up to 30 participants at up to 5 study centers located in Europe and the United Kingdom. The main questions this clinical trial aim to answer are: Is it safe? Does it work? Participants who meet eligibility criteria will have up to two procedures 30 days apart, in which up to 3 implants will be placed in each lung during the procedure(s). Participants will be asked to return for follow-up visits at…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over (terminated evaluation)
Respiratory / COPD / Asthma · 25 Aug 2026
Evaluation terminated: Brensocatib for non-CF bronchiectasis is no longer under NICE appraisal—do not initiate new treatment pathways for this indication pending alternative…
View guideline →
Clinical Brief
There’s a reason child vaccination rates are falling – and it’s not social media
Respiratory / COPD / Asthma · BBC Health · 03 Aug 2026
Vaccination rates declining across UK: Child immunisation coverage is falling below safe thresholds needed for herd immunity, creating vulnerability to vaccine-preventable disease…
View brief →
Guideline
UK Achondroplasia Network’s consensus guideline for multidisciplinary care of children and young people with achondroplasia: NICE review
Respiratory / COPD / Asthma · 19 May 2026
Establish multidisciplinary team review at diagnosis and at key developmental stages (infancy, pre-school, school age, adolescence) to monitor for complications including spinal…
View guideline →
Clinical Brief
Motherhood not all warm and fuzzy: Bollywood actor’s play spotlights messier side
Respiratory / COPD / Asthma · BBC Health · 09 Jul 2026
Maternal mental health and wellbeing deserve greater clinical recognition and discussion, as societal expectations often diminish the psychological burden of motherhood Healthcare…
View brief →
Clinical Brief
‘It’s not a nice world to bring children into’: Births fall to the lowest level in 50 years
Respiratory / COPD / Asthma · BBC Health · 27 May 2026
Record low fertility rates: Live births in England and Wales have fallen to their lowest level in 50 years, reflecting significant demographic…
View brief →
Guideline
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
Respiratory / COPD / Asthma · 17 Jun 2026
Mepolizumab is recommended for patients with uncontrolled COPD and blood eosinophils ≥100 cells/μL; check eosinophil levels before initiating treatment as this is…
View guideline →